Session » Muscle Biology, Myositis & Myopathies Poster (0683–0722)

Date: Sunday, November 7, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 0685

Adipokines and Loss of Lean Mass Among Patients with Rheumatoid Arthritis

8:30AM-10:30AM: Abstract Number: 0704

Anti-SSa/SSb and Ro52 and Interstitial Lung Disease in Idiopathic Inflammatory Myopathies

8:30AM-10:30AM: Abstract Number: 0696

Anti-Transcriptional Intermediary Factor 1-gamma Antibodies in Dermatomyositis with and Without Cancer – A Longitudinal Study

8:30AM-10:30AM: Abstract Number: 0717

Association of Fatigue with Disease Activity in Myositis

8:30AM-10:30AM: Abstract Number: 0707

Association of Pneumomediastinum with Poor Prognosis in Patients with Myositis-Associated Interstitial Lung Disease

8:30AM-10:30AM: Abstract Number: 0708

Cardiovascular Risk in Myositis Patients Compared to General Population – Preliminary Data from a Single-centre Cross-sectional Study

8:30AM-10:30AM: Abstract Number: 0703

CD8 Positron Emission Tomography (PET/CT) Imaging with 89Zr-Df-IAB22M2C in Patients with Inclusion Body Myositis

8:30AM-10:30AM: Abstract Number: 0699

Clinical Characteristics of Idiopathic Inflammatory Myositis Manifesting with Myoglobinuria: A 15 Year Retrospective Review

8:30AM-10:30AM: Abstract Number: 0687

Clinical Features and Prognosis of a Large North American Cohort of Adult MDA5+ Dermatomyositis

8:30AM-10:30AM: Abstract Number: 0700

Clinical Outcomes in Idiopathic Inflammatory Myositis Within the Military Health System: A 15 Year Retrospective Review

8:30AM-10:30AM: Abstract Number: 0697

Detection of Autoantibodies Against Muscle-Specific Four-and-a-Half-LIM Domain 1 (FHL1) in Inflammatory Myopathies: Results from a Single-Center Cohort

8:30AM-10:30AM: Abstract Number: 0714

Diagnostic Accuracy of Electromyogram for Myositis

8:30AM-10:30AM: Abstract Number: 0693

Discovery of Antigen Specific CD4+ T Cells in Anti-HMGCR-positive Immune Mediated Necrotizing Myopathy

8:30AM-10:30AM: Abstract Number: 0684

Extended Report: Successful Treatment anti-MDA5 Antibody-positive Interstitial Lung Disease with Plasma Exchange Therapy

8:30AM-10:30AM: Abstract Number: 0698

Flow Cytometry and Sorting of Single Antibody Secreting Cells from Frozen Muscle Tissue

8:30AM-10:30AM: Abstract Number: 0694

Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Fiber Necroptosis and Muscle Inflammation and Ameliorates Muscle Weakness in Experimental Polymyositis

8:30AM-10:30AM: Abstract Number: 0715

High-Dimensional Analysis Reveals Abnormal B Cell Subsets Associated with Specific Changes to Circulating T and Myeloid Cell Populations in Patients with Idiopathic Inflammatory Myopathies

8:30AM-10:30AM: Abstract Number: 0712

Immune Checkpoint Inhibitor-related Myotoxicity : Musculoskeletal and/or Neuromuscular Junction Disorder ?

8:30AM-10:30AM: Abstract Number: 0692

Immunophenotyping of Inclusion Body Myositis Blood T Cells: Pathogenic and Biomarker Implications

8:30AM-10:30AM: Abstract Number: 0690

Impact of Achieving 2016 ACR/EULAR Response Criteria on Patient Centered Outcome Measures in Myositis

8:30AM-10:30AM: Abstract Number: 0689

Incidence, Prevalence, and Mortality of Dermatomyositis: A Population-based Cohort

8:30AM-10:30AM: Abstract Number: 0719

Increased Risk of Venous Thromboembolism in Adult Patients with Idiopathic Inflammatory Myopathies

8:30AM-10:30AM: Abstract Number: 0686

Is It Useful to Assess Muscle Involvement with Positron Emission Tomography in Patients with Idiopathic Inflammatory Myositis? A Case-Control Study

8:30AM-10:30AM: Abstract Number: 0709

Lower HDL-associated Apolipoprotein A-I Levels Associate with Presence of Calcinosis in Adult Dermatomyositis

8:30AM-10:30AM: Abstract Number: 0716

Marked Capillary Basement Membrane Reduplication Is the Hallmark Histopathological Feature of Scleromyositis

8:30AM-10:30AM: Abstract Number: 0713

MDA5 Helicase Domains Identified as the Main Targets of Anti-MDA5 Autoantibodies in European Dermatomyositis Patients

8:30AM-10:30AM: Abstract Number: 0705

Mitochondrial Calcification-Induced Inflammation in Human Skeletal Muscle and Immune Cells

8:30AM-10:30AM: Abstract Number: 0706

Mycophenolate Mofetil and Methotrexate Efficacy in Dermatomyositis

8:30AM-10:30AM: Abstract Number: 0722

Myostatin in Idiopathic Inflammatory Myopathies: Seric Assessment and Disease Activity

8:30AM-10:30AM: Abstract Number: 0718

Pain Severity and Interference in Adult Autoimmune Inflammatory Myopathies

8:30AM-10:30AM: Abstract Number: 0710

Patients with Recent Onset, Active Polymyositis (PM), Dermatomyositis (DM) and Antisynthetase Syndrome (ASS) Have Reduced Muscle Endurance but Not Reduced Muscle Strength Compared to Patients with Established, Low-active Disease

8:30AM-10:30AM: Abstract Number: 0702

Performance of Commercial Autoantibody Testing in Comparison to Recognized Gold Standards in Myositis Autoantibody Testing

8:30AM-10:30AM: Abstract Number: 0683

Predictors of Rapidly Progressive Interstitial Lung Disease and Mortality in Patients with Autoantibodies Against Melanoma Differentiation-Associated Protein 5 Dermatomyositis

8:30AM-10:30AM: Abstract Number: 0695

Safety and Tolerability of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial

8:30AM-10:30AM: Abstract Number: 0691

Serum Cytokine Profiles of Patients with Adult Idiopathic Inflammatory Myopathy

8:30AM-10:30AM: Abstract Number: 0688

Standardized Prevalence Ratios of Cancer in Idiopathic Inflammatory Myositis

8:30AM-10:30AM: Abstract Number: 0711

Suppression of HDL-associated Apolipoprotein A-I (apoA-I) Levels in Patients with Idiopathic Inflammatory Myopathies

8:30AM-10:30AM: Abstract Number: 0720

The Clinical Significance of anti-PC4 and SFRS1 Interacting Protein 1 Antibody in Polymyositis and Dermatomyositis Patients

8:30AM-10:30AM: Abstract Number: 0721

Timed Function Tests as Measures of Disease Activity and Functional Outcome in Inflammatory Myositis

8:30AM-10:30AM: Abstract Number: 0701

Use and Yield of Computed Tomography as a Cancer Surveillance Method in Idiopathic Inflammatory Myositis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].